ORGANIZATION

• HIV Groups Pin Hopes on MHLW’s Development Requests for Preventive Therapy
  September 4, 2023

• Only 1.2% of NSCLC Patients Receiving Gene Panel Tests: Survey
  September 1, 2023

• Shipments Restricted or Suspended for 22.4% of Products in July, No Sign of Improvement: FPMAJ
  August 31, 2023

• JPMA on Alert for IRA’s Drug Pricing Provisions, Boosting Cooperation with PhRMA
  August 29, 2023

• As 2040 Doctor Shortage Looms, Japan Consumer Healthcare Group Pushes Rx-to-OTC Switches for Hypertension Meds
  August 25, 2023

• Japan Citizens’ Group Objects to HPV Vaccination in Males
  August 25, 2023

• JPMA Taskforce Issues Proposal on Information Supply, Drug Development for Rare Diseases
  August 18, 2023

• Economic Burden of Preventable Cancer “Over 1 Trillion Yen”: NCC, NCGM
  August 17, 2023

• INES Proposes Extension of Public Funding for COVID Drugs
  August 7, 2023

• IRA Could Create New Type of Drug Loss, Affecting Japan Too: PhRMA Official
  July 31, 2023

• Shipments of 22.3% of Products Restricted or Suspended in June: FPMAJ
  July 24, 2023

• JPA to Issue Policy Proposal to Address Lingering Supply Crisis
  July 24, 2023

• More People Seek Self-Medication Tax Break in 2022
  July 24, 2023

• JPMA Says IRA Is “Alarming,” Set to Exchange Views with PhRMA
  July 21, 2023

• Pseudonymised Data Should Fuel Orphan Drug Discovery, but Criteria and Overseas Usage Must Be Discussed: JPMA
  July 21, 2023

• Policy Veterans’ Group Lauds Expert Panel’s Report as “Epoch Making”
  July 20, 2023

• Drug Reps in Japan Decline for 9th Consecutive Year, Falling Below 50,000: FY2022 Report
  July 19, 2023

• Reform Regenerative Medicine Systems to Fight Lag, Loss: FIRM to Japan Govt
  July 12, 2023

• Stop Requiring Japanese PI Data for Global Products: JPMA Officials
  July 10, 2023

• PhRMA Urges Japan to Offer Coverage for CGP Testing in First-Line Setting
  July 4, 2023

ページ

• « 先頭
• ‹ Prev
• …
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• …
• Next ›
• 最終 »